Archive for the ‘Latest Research’ Category
4DMT Now Recruiting for Natural History Studies!
February 10th, 2017 by Cory MacDonald
4D Molecular Therapeutics Enrolling Patients in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia
4DMT is accepting inquires from interested choroideremia (CHM) patients for their upcoming Natural History Study. In partnership with the Choroideremia
Gene Therapy Trial Results Released!
April 27th, 2016 by Cory MacDonald
In a letter published by the New England Journal of Medicine today, Dr. Robert Maclaren released positive long-term results from
CRF Announces Partnership With 4DMT
February 23rd, 2016 by Chris Moen
4D Molecular Therapeutics and the Choroideremia Research Foundation Partner to Develop Gene Therapy Treatment for Choroideremia
Gene Therapy Trials Begin in Germany
January 21st, 2016 by Cory MacDonald
At Tübingen Department of Ophthalmology in Germany, the first gene therapy trial for Choroideremia patients began on January 13th. This
Spark Announces Phase 3 Data for LCA Trial
October 5th, 2015 by Chris Moen
An announcement today by Spark Therapeutics brings the world one step closer toward a commercially available gene therapy treatment. This
Clinical Trials Announced in Miami
September 19th, 2015 by Chris Moen
The Bascom Palmer Eye Institute at the University of Miami has announced the opening of a clinical trial using gene
Gene Therapy Clinical Trials Begin in Canada
May 28th, 2015 by Chris Moen
The University of Alberta, in coordination with NightstaRx, have initiated a clinical trial for patients with Choroideremia using NightstaRx’s gene
Nightstar Receives U.S. and European Orphan Drug Designation for Gene Therapy to Treat Choroideremia
March 24th, 2015 by Cory MacDonald
PRESS RELEASE: London, 11 January 2015 – NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies
SPARK Therapeutics pulls off a $161M IPO
January 30th, 2015 by Danny Boren
Spark Therapeutics, the Philadelphia firm specializing in gene therapy treatments who just last week announced the start of the United States first